Immunic (NASDAQ:IMUX) Stock Rating Lowered by StockNews.com

Immunic (NASDAQ:IMUX) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a report issued on Thursday.

IMUX has been the subject of several other research reports. Brookline Capital Management reiterated a “buy” rating and issued a $10.00 target price on shares of Immunic in a research note on Friday, April 5th. Piper Sandler reiterated an “overweight” rating and issued a $28.00 price objective on shares of Immunic in a research note on Tuesday, July 16th.

Immunic Stock Performance

NASDAQ IMUX traded up $0.01 on Thursday, hitting $1.39. 101,623 shares of the stock traded hands, compared to its average volume of 595,299. The firm has a market capitalization of $125.21 million, a price-to-earnings ratio of -0.76 and a beta of 1.77. The business’s fifty day moving average is $1.24 and its two-hundred day moving average is $1.27. Immunic has a 12 month low of $0.95 and a 12 month high of $2.45.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.02. Analysts expect that Immunic will post -0.94 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in IMUX. Virtu Financial LLC bought a new position in Immunic in the 1st quarter valued at $25,000. Ikarian Capital LLC raised its position in shares of Immunic by 258.3% in the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after buying an additional 1,162,378 shares in the last quarter. Janus Henderson Group PLC bought a new stake in Immunic during the first quarter valued at $9,266,000. BVF Inc. IL purchased a new position in Immunic during the first quarter worth about $11,752,000. Finally, Vanguard Group Inc. grew its position in Immunic by 100.7% during the first quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock worth $4,480,000 after buying an additional 1,703,047 shares in the last quarter. Hedge funds and other institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.